The present invention relates to a process of producing isobutanol, including: mixing water, lactate, an enzyme mixture including at least one enzyme, at least one cofactor, and at least one coenzyme, to prepare a reaction mixture; allowing catalytic conversions of lactate in the reaction mixture for a sufficient amount of time to produce isobutanol; and separating the isobutanol from a reactant obtained by the catalytic conversions, in which the conversion of lactate into isobutanol is in association with a NADH.sup.+/NADH and/or NADP.sup.+/NADPH regenerating system.

A biopolymer, which exists in a liquid phase at room temperature, a use thereof, and a preparation method therefor are provided.

The present invention provides methods for treating subjects suffering from a kidney stone disease carrying a heterozygous AGXT gene variant, methods for identifying such subjects, and compositions comprising nucleic acid inhibitors, e.g., double stranded ribonucleic acid (dsRNA) agents or single stranded antisense polynucleotide agents targeting lactate dehydrogenase A (LDHA) and/or hydroxyacid oxidase (HAO1), for treating such subjects.

The present invention relates to: acid-resistant yeast to which lactic acid productivity is imparted, and in which the conversion of pyruvate into acetaldehyde is inhibited and, consequently, the ethanol production pathway is inhibited; and a method for producing lactic acid by using same.

This invention relates to compounds, compositions, and methods useful for reducing lactate dehydrogenase target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.

Described herein are plasmid addiction systems comprising a host cell comprising one or more inactivated host cell essential genes; and a plasmid comprising one or more plasmid essential genes operably linked to a constitutively active promoter. Also described herein are metabolism-based plasmid addiction systems (PAS) comprising a host cell and a plasmid operably linked to a constitutively active promoter for producing value-based products (e.g., 1-butanol) and methods of generating PASs in microorganisms and producing 1-butanol from a PAS in the absence of antibiotics and/or co-inducers.

The present invention provides tools and methods for producing organic acids using strains of Monascus which are tolerant to high organic acid concentrations at low pH.

The invention relates to a genetically engineered thermophilic bacterial cell that is facultative anaerobic comprising: a) inactivation or deletion of the endogenous (S)-lactate dehydrogenase gene; b) introduction of a (R)-lactate dehydrogenase gene; c) inactivation or deletion of the endogenous pyruvate formate lyase A and/or B gene.

Provided are mammalian cells devoid of lactate dehydrogenase activity.

The present invention relates to anticancer extracellular vesicles, a preparation method therefor, and an anticancer composition comprising same. Immune-tolerized extracellular vesicles containing LDHB and PGC-1α of the present invention provide cancer treatment, suppression of cancer metastasis, and cancer prevention technologies by normalizing cancer cell-specific aerobic glycolysis energy metabolic pathway in which lactate and hydrogen ions, which form a tumor microenvironment favorable for immune evasion, proliferation, metastasis and invasion of cancer cells, are produced, thereby enabling tumors to be effectively removed by means of the immune system of a patient.